EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer-Reference-Cited by-同舟云学术

EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer

Published:2019-09 Issue:17 Volume:14 Page:2315-2338
ISSN:1743-5889
Container-title:Nanomedicine
language:en
Short-container-title:Nanomedicine

Author:

Asik Elif¹²,Akpinar Yeliz³⁴,Caner Ayse¹,Kahraman Nermin¹,Guray Tulin²,Volkan Murvet³,Albarracin Constance⁵,Pataer Apar⁶,Arun Banu⁷,Ozpolat Bulent¹⁸

Affiliation:

1. Department of Experimental Therapeutics, The University of Texas-MD Anderson Cancer Center, Houston, TX 77054, USA

2. Department of Biotechnology, Middle East Technical University, Ankara 06800, Turkey

3. Department of Chemistry, Middle East Technical University, Ankara 06800, Turkey

4. Department of Chemistry, Kırsehir Ahi Evran University, Kırsehir 40100, Turkey

5. Department of Pathology, Division of Pathology/Lab Medicine, MD Anderson Cancer Center, Houston, TX 77054, USA

6. Department of Thoracic Surgery, MD Anderson Cancer Center, Houston, TX 77054, USA

7. Departments of Breast Medical Oncology & Breast Cancer Genetics, The University of Texas-MD Anderson Cancer Center, Houston, TX 77054, USA

8. Center for RNA Interference & Non-Coding RNA, The University of Texas-MD Anderson Cancer Center, Houston, TX 77054, USA

Abstract

Aim: To investigate the role of EF2K in BRCA1-mutated breast cancer. Materials & methods: We developed silica coated cobalt-ferrite (CoFe) nanoparticles for in vivo delivery of small interfering RNAs (siRNAs) into BRCA1-mutated breast cancer. Results: Expression of EF2K is highly upregulated in the majority (78.5%) of BRCA1-mutated patients and significantly associated with poor patient survival and metastasis. Silencing of EF2K reduced cell proliferation, migration and invasion of the cancer cells. In vivo therapeutic targeting of EF2K by CoFe-siRNA-nanoparticles leads to sustained EF2K gene knockdown and suppressed tumor growth in orthotopic xenograft models of BRCA1-mutated breast cancer. Conclusion: EF2K is a potential novel molecular target in BRCA1-mutated tumors and CoFe-based siRNA nanotherapy may be used as a novel approach to target EF2K.

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nnm-2019-0132

Reference65 articles.

1. A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1

2. Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2

3. Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification

4. The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in BRCA1 and BRCA2

5. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advancements in small interfering RNA based therapeutic approach on breast cancer;European Journal of Pharmacology;2024-10

2. MBD2 facilitates tumor metastasis by mitigating DDB2 expression;Cell Death & Disease;2023-05-04

3. siRNA and targeted delivery systems in breast cancer therapy;Clinical and Translational Oncology;2022-12-23

4. MBD2 facilitates tumor metastasis by mitigating DDB2 expression;2022-11-30

5. Trends in iron oxide nanoparticles: a nano-platform for theranostic application in breast cancer;Journal of Drug Targeting;2022-07-03